Clinical Trials
17
Active:16
Completed:1
Trial Phases
3 Phases
Phase 1:15
Phase 2:1
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Phase 1
15 (88.2%)Phase 2
1 (5.9%)Phase 4
1 (5.9%)Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Phase 4
Active, not recruiting
- Conditions
- Lymphoma, B-CellLeukemia, B-cellSolid TumorLymphoma, Non-HodgkinGraft Vs Host Disease
- Interventions
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 297
- Registration Number
- NCT03229200
- Locations
- 🇺🇸
Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center, Burbank, California, United States
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-03-16
- Lead Sponsor
- Pharmacyclics Switzerland GmbH
- Target Recruit Count
- 74
- Registration Number
- NCT02902965
- Locations
- 🇨🇿
Fakultní nemocnice Brno, Brno, Czechia
🇨🇿Fakultní nemocnice Hradec Králové, Nový Hradec Králové, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czechia
News
No news found